Phaseline

Companies › Novo Nordisk

Novo Nordisk: clinical trials, targets and expected readouts

37 active drug programs in 220 registered trials: 71 Phase 3, 54 Phase 1, 52 Phase 4, 43 Phase 2; Metabolic and endocrine, Cardiovascular, Hematology, Gastroenterology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Semaglutide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 4Obesity; Cardiovascular Risk; Cardiovascular Disease; Diabetes Mellitus, Type 2 …Dec 2026
Insulin icodec
Insulin receptor agonist
INSRPhase 4Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1Jan 2027
Eptacog Alfa (Activated)
Coagulation factor VII exogenous protein
F7Phase 4Severe Postpartum HaemorrhageAug 2027
Liraglutide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 3Obesity; Type 2 Diabetes Patients; Atrial Fibrillation; Severe Obesity …Dec 2026
Somapacitan
Growth hormone receptor agonist
GHRPhase 3SGA, Turner Syndrome, Noonan Syndrome, ISS; SGA; Short Stature Children Born Small for Gestational Age (SGA)Dec 2026
Ziltivekimab
Interleukin-6 inhibitor; Interleukin-6 binding agent
IL6Phase 3Heart Failure; Cardiovascular Risk; Myocardial InfarctionJan 2027
Cagrilintide B
Dual GLP-1/glucagon receptor agonist
GLP1R, GCG, CALCRPhase 3Obesity; Overweight; Cardiovascular Disease; Diabetes Mellitus, Type 2Jan 2027
Concizumab
Tissue factor pathway inhibitor inhibitor
TFPIPhase 3Haemophilia A With Inhibitors; Haemophilia A Without Inhibitors; Haemophilia A and B With and Without InhibitorsFeb 2027
CagriSema
Amylin and GLP-1 receptor agonist combination
GLP1R, CALCRPhase 3Obesity; Diabetes Mellitus, Type 2; OverweightJun 2027
Etavopivat
Pyruvate kinase isozymes R/L activator
PKLRPhase 3Sickle Cell DiseaseAug 2027
NNC0487-0111
Mechanism unknown
–Phase 3Obesity; Diabetes Mellitus; OverweightNov 2027
NNC6019-0001
Unclear - mechanism not specified in registry text
–Phase 3Transthyretin Amyloid Cardiomyopathy (ATTR CM)Feb 2028
Zenagamtide
GLP-1/GIP receptor agonist
GLP1R, GIPRPhase 3Overweight; Type 2 DiabetesJun 2028
Denecimig (Mim8)
Recombinant Factor VIII replacement
F8Phase 3Haemophilia AJun 2028
NNC0662-0419
GLP-1 receptor agonist
–Phase 2Overweight; Obesity; Diabetes Mellitus, Type 2Dec 2026
CDR132L
Antisense oligonucleotide targeting CAMKII delta
–Phase 2Heart Failure; Healthy VolunteersDec 2026
UBT251
GLP-1 receptor agonist
–Phase 2Overweight; Diabetes Mellitus, Type 2; ObesityJan 2027
NNC0519-0130–Phase 2Chronic Kidney Disease–
NNC0537-1482–Phase 1Heart FailureJan 2027
NNC4004-0002
Serum uric acid-lowering agent
–Phase 1Healthy VolunteersJan 2027
NNC6989-0001–Phase 1OverweightJan 2027
NNC0480-0389
GIP receptor agonist
GIPRPhase 1OverweightJan 2027
NNC0113-5840–Phase 1ObesityJan 2027
NNC0442-0344 A (Inno8)
unclear - mechanism not specified for haemophilia A
–Phase 1Haemophilia AFeb 2027
NNC4005-0001–Phase 1Fatty Liver DiseaseMay 2027
Coramitug
Anti-transthyretin (TTR) monoclonal antibody; promotes removal of TTR amyloid deposits and
TTRPhase 1Transthyretin Amyloid CardiomyopathyMay 2027
NNC0705-0002
Anti-inflammatory agent targeting heart and metabolic health
–Phase 1Healthy VolunteersAug 2027
NNC6022-0004–Phase 1ObesityAug 2027
NNC0642-1895–Phase 1Healthy VolunteersSep 2027
INV-347–Phase 1ObesitySep 2027
NNC0721-8060–Phase 1OverweightSep 2027
NNC0581-0001–Phase 1Healthy VolunteersOct 2027
NNC0638-0355
GLP-1 receptor agonist
–Phase 1ObesityOct 2027
NNC0497-0040–Phase 1Type 1 Diabetes (T1D)Feb 2028
NNC9733-0001
GLP-1 receptor agonist
–Phase 1Healthy VolunteerMar 2028
NNC1679-0001–Phase 1Healthy VolunteersJun 2028
NNC0194-0499–Phase 1Diabetes Mellitus, Type 1–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05567796Cagrilintide BPhase 3ObesityMetabolic and endocrineOct 2024
NCT05567796SemaglutidePhase 3ObesityMetabolic and endocrineOct 2024
NCT05567796CagriSemaPhase 3ObesityMetabolic and endocrineOct 2024
NCT03087032LiraglutidePhase 4Type 2 Diabetes PatientsMetabolic and endocrineJan 2025
NCT06410352SemaglutidePhase 4Metabolic SyndromeMetabolic and endocrineSep 2025
NCT04873050SemaglutidePhase 4Pre DiabetesMetabolic and endocrineJan 2026
NCT03899402SemaglutidePhase 2Type 1 Diabetes MellitusMetabolic and endocrineJan 2026
NCT06827002SemaglutidePhase 1Obesity and OverweightMetabolic and endocrineFeb 2026
NCT07374328SemaglutidePhase 1Type 2 DiabetesMetabolic and endocrineMay 2026
NCT07272343SemaglutidePhase 4Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineJun 2026
NCT05424003SemaglutidePhase 2NAFLDGastroenterologyAug 2026
NCT06717698NNC0519-0130Phase 2Chronic Kidney DiseaseGenitourinarySep 2026
NCT07087795SemaglutidePhase 1Diabetes Mellitus, Type 1Metabolic and endocrineSep 2026
NCT07087795NNC0194-0499Phase 1Diabetes Mellitus, Type 1Metabolic and endocrineSep 2026
NCT05119179SemaglutidePhase 4PreDiabetesMetabolic and endocrineOct 2026
NCT07513168SemaglutidePhase 4ObesityMetabolic and endocrineDec 2026
NCT05726227SemaglutidePhase 3ObesityMetabolic and endocrineDec 2026
NCT07225816LiraglutidePhase 1ObesityMetabolic and endocrineDec 2026
NCT07225816SemaglutidePhase 1ObesityMetabolic and endocrineDec 2026
NCT07225816SemaglutidePhase 1ObesityMetabolic and endocrineDec 2026
NCT07184632NNC0662-0419Phase 2OverweightMetabolic and endocrineDec 2026
NCT05195944SemaglutidePhase 4Liver Transplant; ComplicationsGastroenterologyDec 2026
NCT06396416SemaglutidePhase 4ObesityGenitourinaryDec 2026
NCT07059377SemaglutidePhase 3Diabetes Mellitus, Type 2PsychiatryDec 2026
NCT05067621SemaglutidePhase 2Type 2 Diabetes MellitusMetabolic and endocrineDec 2026
NCT03878446SomapacitanPhase 2Short Stature Children Born Small for Gestational Age (SGA)OtherDec 2026
NCT07223242SemaglutidePhase 2HFpEF - Heart Failure With Preserved Ejection FractionMetabolic and endocrineDec 2026
NCT05254314SemaglutidePhase 2AsthmaRespiratoryDec 2026
NCT03856632LiraglutidePhase 4Atrial FibrillationCardiovascularDec 2026
NCT05780905SemaglutidePhase 4Diabetes Mellitus, Type 2NeurologyDec 2026
NCT06461377SemaglutidePhase 4Type 2 DiabetesMetabolic and endocrineDec 2026
NCT06005012SemaglutidePhase 2Fibrosis, LiverGastroenterologyDec 2026
NCT04451837SemaglutidePhase 2Type2 DiabetesMetabolic and endocrineDec 2026
NCT05173714SemaglutidePhase 2Chronic Kidney DiseasesGenitourinaryDec 2026
NCT07656454CDR132LPhase 1Healthy VolunteersCardiovascularDec 2026
NCT06200207ZiltivekimabPhase 3Heart FailureCardiovascularJan 2027
NCT07395687UBT251Phase 2OverweightMetabolic and endocrineJan 2027
NCT07029009LiraglutidePhase 2Maturity Onset Diabetes of the YoungMetabolic and endocrineJan 2027
NCT07297589SemaglutidePhase 3STEMI - ST Elevation Myocardial InfarctionCardiovascularJan 2027
NCT06894784SemaglutidePhase 3Diabetes Type 1Metabolic and endocrineJan 2027
NCT06691243SemaglutidePhase 2Cocaine Use DisorderInfectious diseaseJan 2027
NCT06387199SemaglutidePhase 2Type 1 DiabetesMetabolic and endocrineJan 2027
NCT07218627NNC0537-1482Phase 1Heart FailureCardiovascularJan 2027
NCT06859073NNC4004-0002Phase 1Healthy VolunteersMetabolic and endocrineJan 2027
NCT07437079NNC6989-0001Phase 1OverweightMetabolic and endocrineJan 2027
NCT07076199Insulin icodecPhase 3Diabetes Mellitus, Type 1Metabolic and endocrineJan 2027
NCT07411560Cagrilintide BPhase 1OverweightMetabolic and endocrineJan 2027
NCT07411560NNC0480-0389Phase 1OverweightMetabolic and endocrineJan 2027
NCT06118281ZiltivekimabPhase 3Cardiovascular RiskCardiovascularJan 2027
NCT06937060SemaglutidePhase 3Psoriasis (PsO)ImmunologyJan 2027
NCT07566390NNC0113-5840Phase 1ObesityMetabolic and endocrineJan 2027
NCT07220564NNC0442-0344 A (Inno8)Phase 1Haemophilia AHematologyFeb 2027
NCT04775082LiraglutidePhase 3ObesityMetabolic and endocrineFeb 2027
NCT07242534SemaglutidePhase 4InfertilityMetabolic and endocrineFeb 2027
NCT07223983SemaglutidePhase 1Alcohol Use DisorderMetabolic and endocrineFeb 2027
NCT04083781ConcizumabPhase 3Haemophilia A With InhibitorsHematologyFeb 2027
NCT07401992SemaglutidePhase 4Psoriasis (PsO)Metabolic and endocrineFeb 2027
NCT07011667Cagrilintide BPhase 3ObesityMetabolic and endocrineMar 2027
NCT07011667SemaglutidePhase 3ObesityMetabolic and endocrineMar 2027
NCT07314684SemaglutidePhase 4T2DM (Type 2 Diabetes Mellitus)ImmunologyMar 2027

The 60 nearest readouts of 220 trials; the rest in the app.

From the company's SEC filings

Cash of 26.5bn DKK on 2025-12-31; operating cash flow positive

Complete response letters from FDA

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GLP1R (5) CALCR (2) GIPR (2) GCG (1) GHR (1) TTR (1) IL6 (1) F7 (1) INSR (1) TFPI (1) PKLR (1) F8 (1)

Companies with the same targets

Eli Lilly Roche AstraZeneca Hangzhou Sciwind Biosciences Amgen Regeneron Pharmaceuticals Pfizer Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company Viking Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.